Finally, evidence to date suggests that CD40+ DC activation is a critical and nonredundant mechanism to convert “cold” tumors (i.e., lacking a T cell tumor infiltrate) into “hot” ones (i.e., having a prominent T cell tumor infiltrate), sensitizing them to checkpoint inhibition therapy [104,105]. The gene discussed is CD40; the disease is neoplasm.